Rivaroxaban: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AWMSG (Wales), NICE (England) and PHARMAC (New Zealand), among others, recommended or restricted rivaroxaban, while CIPM (Spain) and CONITEC (Brazil) did not recommend it.
HAS (France) has been harder on rivaroxaban than on its own caseload: it refused 2 of 5 decisive submissions here (40%), against a base rate of 11% across everything it has assessed.
The file has been open for more than a decade: 15.6 years separate the first record, 8 Dec 2008 at SMC (Scotland), from the most recent, 2024 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2019, recommended by 2024, after a resubmission.
No assessment is on file from G-BA (Germany), which is among the eight highest-volume agencies here.
The programme is broad: 15 distinct indication wordings are recorded for rivaroxaban by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 55 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess rivaroxaban, on 8 Dec 2008; AIFA (Italy) did not open a file until 18 Jan 2021 — an unusually long tail of 12.1 years between the earliest and latest system to look at it.
The record arrives in waves: 13 separate years each carry two or more decisions, spread across 15 years in total.
9 of the 11 agencies here assessed rivaroxaban more than once, HAS (France) most often at 13 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for rivaroxaban.
The full ledger for rivaroxaban reads 23 recommended, 9 not recommended, 9 other and 8 restricted, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2024 | Prevention of venous thromboembolismChronic stable atherosclerotic disease (CSAD) | Recommended | source |
| HAS (France) | 21 Sep 2022 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
| AWMSG (Wales) | 7 Nov 2018 | Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with coronary … | excluded, NICE appraised | source |
| TLV (Sweden) | 31 Jan 2018 | Xarelto 2,5 mg ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| PHARMAC (New Zealand) | 16 Mar 2016 | Venous thromboembolism (VTE): treatment and prevention | PTAC advice: No Formal Recommendation · decision reached | source |
50 further decisions for rivaroxaban, across 11 agencies, are not shown here. They link to 37 further source documents.
Related molecules
- apixaban — same ATC class B01A — Antithrombotics
- enoxaparin — same ATC class B01A — Antithrombotics
- dabigatran — same ATC class B01A — Antithrombotics
- fondaparinux — same ATC class B01A — Antithrombotics
- ticagrelor — same ATC class B01A — Antithrombotics
- clopidogrel — same ATC class B01A — Antithrombotics
Coverage: 55 decisions for rivaroxaban from 11 agencies, 2008 to 2024. Data to 7 Sep 2026. ATC class B01A — Antithrombotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.